Home

Crescendo Biologics announces clinical biodistribution data of Humabody® bispecific CB307 at ESMO 2024

View PDF

Crescendo Biologics announces that Zai Lab has initiated a global Phase 2 clinical trial evaluating ZL-1102 (Humabody®, CB001) as a topical treatment for psoriasis

View PDF

Crescendo Biologics presents preclinical data on lead clinical candidate CB307 and unveils its first ‘2 in 1’ immune cell engager CB699 at AACR 2024

View PDF

Crescendo Biologics announces publication in Neoplasia of preclinical tumour penetration data supporting CB307

View PDF

Crescendo Biologics announces first U.S. patients dosed in expanded Phase 1b clinical trial of CB307 for patients with mCRPC

View PDF

Crescendo Biologics wins significant European Patent Office ruling related to the engineering of immunoglobulin technology

View PDF